Exploring Tumor Biology in Ovarian Cancer with Advanced Imaging Techniques
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
This study is testing new imaging techniques to better understand ovarian cancer tumors and improve personalized treatment for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT06084195 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the understanding of tumor heterogeneity in high-grade serous ovarian cancer by integrating in vivo MRI imaging with ex vivo histological and molecular assessments. Patients will undergo imaging before surgery, and tissue and blood samples will be collected during the surgical procedure for further analysis. The goal is to develop non-invasive methods for characterizing tumors, which could lead to more personalized treatment approaches.
Who should consider this trial
Good fit: Ideal candidates are patients over 18 years old with advanced-stage high-grade serous ovarian cancer who are eligible for surgery.
Not a fit: Patients with early-stage disease, those who will not undergo surgery, or those with significant psychological or social barriers to follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with high-grade serous ovarian cancer.
How similar studies have performed: While the integration of imaging and molecular assessments is a growing field, this specific approach to high-grade serous ovarian cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged \>18 * Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment * Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures, * Patient who has given informed, written and express consent, * Patient affiliated with a French health insurance scheme. Exclusion Criteria: * Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases, * Patient who will not have surgery * Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, * Patient under guardianship, curatorship or safeguarding of justice, * Pregnant and/or nursing patient, * Patient with a history of other cancers within 5 years/10 years prior to inclusion
Where this trial is running
Montpellier
- NOUGARET Stephanie — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: MOUSSION Aurore
- Email: aurore.moussion@icm.unicancer.fr
- Phone: 0467613102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.